Navigation Links
In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells

d of the nerves that connect them to the rest of the body. Approximately one in 100,000 children develops neuroblastoma in the United States.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outc
'"/>




Page: 1 2 3

Related medicine technology :

1. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
2. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
6. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
7. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
8. Researchers Identify Intracellular Pathway of Alfacells Onconase
9. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
10. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
11. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
Post Your Comments:
(Date:12/15/2009)... 15 West Pharmaceutical Services, Inc. (NYSE: ... Directors has approved payment of the first-quarter 2010 cash ... paid on February 3, 2010 to shareholders of record ... ,, West is a global manufacturer of components ... seals for vials, and closures and disposable components used ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Flextronics Completes SloMedical Acquisition 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 1Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3
... is Designed to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying ... of 90 ... Percent., Accurate Diagnosis is Important ... Potential Higher Rates of Severe or Fatal Hemorrhage in Patients With Squamous ...
... 2 DermaGen AB today announced a,cash injection from ... Development and Ostersjostiftelsen. The capital will be used for,the ... be used to initiate a clinical phase 2a study ... has already received approval, and,to further develop the company,s ...
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7DermaGen AB Receives Over 1 Million Euros From a New Share Issue 2DermaGen AB Receives Over 1 Million Euros From a New Share Issue 3
(Date:12/16/2009)... 16 For ages, people from around the ... properties. Its soothing waters have a reputation that dates ... involvement with miracles. Now, with the introduction of two ... can enjoy the legendary benefits of Dead Sea salt ... lines contain all-natural Dead Sea salt and essential oils ...
(Date:12/16/2009)... More Americans have myopia now than in the ,70s, ... Myopia (nearsightedness) is more common in the United States ... National Eye Institute study shows. , Researchers compared National ... and white participants from 1971 to 1972 and from ... The participants were 12 to 54 years old. , ...
(Date:12/16/2009)... trial bottle sample with purchase of 90-count bottle. , ... ... announces a special free offer for a “Free 21-Count ... Formula , with the purchase of a 90-count bottle. Distributed ... in FDA approved facilities and blends the 6 most important medicinal ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... perfect gift to give that special woman who has everything? ... Mary Schook introduces exceptional beauty products online while educating the public ... ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching ... woman who has everything? Why stem cells, of course!, , , ...
Breaking Medicine News(10 mins):Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... Trainers For Peak ... Performance, LOS ANGELES, June 2 ... Cher, now the,Pussycat Dolls are working out with Bally. On the verge of ... for,their hot new single "When I Grow Up," the Pussycat Dolls are getting ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today that it has acquired,Physicians Home Health Care ... $12 million in cash. The transaction will be ... established by a group of physicians in 1984, ...
... of autoantibody-secreting cells, have emerged as promising new ... (RA). In particular, B cell depletion with ... RA patients resistant to standard disease-modifying antirheumatic drugs ... In large trials, about half of these ...
... 2 The International Rett Syndrome,Foundation announced today ... Chief Scientific Officer, beginning July 1. Dr. Horton ... of Rett,Clinics, a series of clinics throughout the ... addition, Dr. Horton will,assist the IRSF Board of ...
... There is still time to enter,the American Academy ... to boys and girls in two groups, grades 3-5 ... will be invited to attend,the 2008 AAP National Conference ... winners will receive $500 and up to $1,000 for ...
Other Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: